Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Stifel

Here's Why Stifel Slashed Price Target On Nike

Stifel analyst Jim Duffy lowered the price target on Nike Inc (NYSE:NKE) to $150 from $160, implying a 23.99% upside. Duffy kept a Buy rating on the shares. The analyst slashed the price target, considering the business restrictions in China due to the rise in COVID-19 cases and the strengthened U.S. dollar position. He said…

Read How Analysts Reacted To MongoDB Post Q1 Earnings Beat

Read How Analysts Reacted To MongoDB Post Q1 Earnings Beat

Analysts appreciated MongoDB, Inc's (NASDAQ:MDB) Q1 beat but cut the price target to reflect macro headwinds. Needham analyst Mike Cikos maintained MongoDB with a Buy rating and lowered the price target from $362 to $310. The price target change reflected the declines in the broader stock market. Cikos acknowledged MongoDB's strong 1QF23 feat outperforming guidance and expectations.…

Camber Energy vs. Centennial Resource Development: Which Oil & Gas Stock is a Better Buy?

Camber Energy vs. Centennial Resource Development: Which Oil & Gas Stock is a Better Buy?

In this article I will analyze and compare Camber Energy (CEI) and Centennial Resource Development (CDEV) to determine which oil & gas stock is currently a better investment.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

2 Cannabis Stocks to Avoid After Stifel Cuts Their Price Targets

Surging inflation and the Fed’s hawkish monetary policy stance could keep the stock market under pressure in the near term. Amid the uncertainties surrounding the economy and the stock market, Stifel analysts are maintaining a negative outlook on the cannabis industry and have cut their price targets for the stocks…

Benzinga's Top Ratings Upgrades, Downgrades For May 12, 2022

Benzinga's Top Ratings Upgrades, Downgrades For May 11, 2022

Stifel Maintains Hold Rating for Inogen: Here's What You Need To Know

Stifel has decided to maintain its Hold rating of Inogen (NASDAQ:INGN) and lower its price target from $40.00 to $30.00. Shares of Inogen are trading down 4.15% over the last 24 hours, at $23.91 per share. A move to $30.00 would account for a 25.5% increase from the current share…

inkl

Read news from The Economist, FT, and more,
with one subscription

Benzinga's Top Ratings Upgrades, Downgrades For May 6, 2022

Benzinga's Top Ratings Upgrades, Downgrades For May 6, 2022

Upgrades For Coupang Inc (NYSE:CPNG), JP Morgan upgraded the previous rating of Neutral to Overweight. The stock has a 52-week-high of $46.00 and a 52-week-low of $11.91. At the end of the last trading period, Coupang closed at $11.99.

Stifel: Weedmaps Best Positioned To Capitalize On Category Growth

Stifel: Weedmaps Best Positioned To Capitalize On Category Growth

In a recent first-quarter outlook report, analysts from Stifel, an American multinational independent investment bank and financial services company, had positive comments on Weedmaps, a tech company serving the cannabis industry,

Benzinga's Top Ratings Upgrades, Downgrades For May 4, 2022

Benzinga's Top Ratings Upgrades, Downgrades For May 4, 2022

Benzinga's Top Ratings Upgrades, Downgrades For April 29, 2022

Benzinga's Top Ratings Upgrades, Downgrades For April 29, 2022

Stifel Maintains Buy Rating for Microsoft: Here's What You Need To Know

Stifel Maintains Buy Rating for Microsoft: Here's What You Need To Know

Stifel has decided to maintain its Buy rating of Microsoft (NASDAQ:MSFT) and lower its price target from $380.00 to $350.00. Shares of Microsoft are trading up 5.64% over the last 24 hours, at $285.45 per share. A move to $350.00 would account for a 22.61% increase from the current share…

Benzinga's Top Ratings Upgrades, Downgrades For April 26, 2022

Benzinga's Top Ratings Upgrades, Downgrades For April 26, 2022

Upgrades According to Susquehanna, the prior rating for Boyd Gaming Corp (NYSE:BYD) was changed from Neutral to Positive. At the moment, the stock has a 52-week-high of $72.72 and a 52-week-low of $50.38. Boyd Gaming closed at $64.20 at the end of the last trading period.

10 Biggest Price Target Changes For Tuesday

10 Biggest Price Target Changes For Tuesday

HC Wainwright & Co. raised Nkarta, Inc. (NASDAQ: NKTX) price target from $25 to $36. Nkarta shares fell 7.2% to $17.38 in pre-market trading.

Get all your
news in one place.

100's of premium titles.
One news app.

RBC Capital Cuts Shopify's Price Target By 23%

Shopify Inc (NYSE:SHOP) (TSX:SHOP) price target has been lowered to $1000 (an upside of 116%) from $1300 by RBC Capital analyst Paul Treiber. The analyst maintained the Outperform rating on the shares. The analyst states that the proposed changes to Shopify’s share structure may be contentious. Treiber adds that while some terms in the proposal…

Stifel Downgrades Rating to Hold for Reynolds Consumer, Lowers Price Target To $31

Stifel downgraded its rating of Reynolds Consumer (NASDAQ:REYN) to Hold with a price target of $31.00, changing its price target from $33.00 to $31.00. Shares of Reynolds Consumer are trading down 3.6% over the last 24 hours, at $28.38 per share.

Read Why Stifel Downgraded Reynolds Consumer Products

Stifel analyst Mark Astrachan downgraded Reynolds Consumer Products Inc (NASDAQ:REYN) to Hold from Buy with a reduced price target of $31, down from $33, implying an 8.7% upside. The analyst has reduced 2022 and 2023 EPS estimates below consensus, reflecting gross margin pressure from higher input costs. Astrachan expects volumes to worsen as the company…

ChemoCentryx Posts Favorable PK, PD Results Of Oral PD-L1 Inhibitor In Cancer

ChemoCentryx Inc (NASDAQ:CCXI) announced the presentation of preclinical data and initial pharmacokinetic (PK) and pharmacodynamic (PD) data from the ongoing Phase 1 study of CCX559 at the American Association for Cancer Research (AACR) Annual Meeting 2022. Preclinical characterization demonstrated that CCX559 is a potent inhibitor of PD-L1 that blocks binding to PD-1 and…

Get all your
news in one place.

100's of premium titles.
One news app.

Another Analyst Gets Cautious Ahead Of Netflix's Q1 After Baird, Stifel

Truist analyst Matthew Thornton lowered the price target on Netflix Inc (NASDAQ: NFLX) to $409 from $470 ahead of its Q1 results. The price target implied an upside of 17.5%.

Stifel Upgrades Rating to Buy for Photronics, Raises Price Target To $21

Stifel upgraded its rating of Photronics (NASDAQ:PLAB) to Buy with a price target of $21.00, changing its price target from $19.00 to $21.00. Shares of Photronics are trading up 4.48% over the last 24 hours, at $15.16 per share.

Here's Why Analysts Expressed Caution Ahead Of Netflix's Q1

Analysts expressed caution ahead of Netflix Inc (NASDAQ:NFLX) Q1 earnings, highlighting EMEA's churn risk, the company's second-largest region, due to potential consumer spending pressure tied to higher energy costs and broader inflationary pressures and loss of subscribers in Russia. Baird analyst William Power noted that each 10 bps increase in churn could negatively…

UBS Remains Bullish On This Social Media Giant - Read Why

UBS analyst Lloyd Walmsley raised the price target on Meta Platforms Inc (NASDAQ:FB) to $300 from $280 and kept a Buy rating on the shares. The price target implies an upside of 29.4%. The impact of the Russia-Ukraine war is more than offset by the company's lower operating expense estimates. Also Read: From 'Facebook' To 'Meta,' 'Facebookers' To…

Stifel Initiates Coverage On Awakn Life Sciences With A Speculative Buy, $8 Target Price Target

Awakn Life Sciences (OTC: AWKNF) is in the news after a respected analyst has upgraded the stock. Awakn is a publicly traded company which trades on the over-the-counter market with the symbol of

Stifel Bumps Up Caesars Entertainment Price Target By 6%

Stifel analyst Steven Wieczynski raised the price target on Caesars Entertainment Inc (NASDAQ:CZR) to $127 from $120 and kept a Buy rating on the shares, implying a 58% upside. Steven mentioned that many potential catalysts for the rest of 2022 should facilitate the shares to return to triple-digit. The analyst also hailed the company's management…

Benzinga's Top Ratings Upgrades, Downgrades For April 1, 2022

1 … 7 8 9 10

People

Mark Zuckerberg

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

US Federal Reserve

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Monetary Policy

Places

367,470 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play